Project Grant R01CA303579
Award Date 9/19/25
Completion Date 8/31/29
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant on August 11, 2025 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The grant is supporting the development of a novel antibody-drug/toxin conjugate (ATC) that leverages a bacterial toxin to promote phagocytosis and cross-presentation of tumor antigens by antigen-presenting cells, with the goal of generating antitumor immune responses for cancer immunotherapy. Key...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- This Project Grant award of $490,500.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research conducted by The University of Texas MD Anderson Cancer Center in Houston, TX. The grant aims to combine TROP2-directed CAR-NK cells with HIF2A inhibition for the immunotherapy of pancreatic cancer. This translational research initiative seeks to develop an innovative approach to treating pancreatic cancer by leveraging...
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Lifengine Animal Health Laboratories Incorporated. The purpose of this Phase I grant is to demonstrate the feasibility of producing chimeric antigen receptor (CAR)-T cells that overexpress the transcription factor C-MYB to enhance their anti-tumor activity and limit functional exhaustion. Lifengine will leverage its proprietary GeneWeld gene editing platform to...
- The Department of the Army Medical Command awarded a $4,275,962 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to The University of Texas M.D. Anderson Cancer Center (MD Anderson) on September 15, 2024. The grant supports a 4-year research initiative to develop CD79B-targeting CAR T-cell therapy for B-cell lymphomas. MD Anderson, a prominent academic cancer research and treatment institution, will leverage its expertise in immunotherapy,...
- The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) on July 2, 2025. The grant supports research aimed at developing a new therapy for aggressive diffuse-type gastric cancer (DGAC), which has limited treatment options and a poor prognosis. Key objectives include uncovering the mechanisms of DGAC tumorigenesis and identifying drug candidates that can target the root cells driving...
- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $1,125,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Kure Ai Inc. located in Shaker Heights, Ohio. The grant will fund the development and clinical testing of an "ultra-fast" (less than 1 day) manufacturing process for chimeric antigen receptor (CAR) T cell therapies, a novel approach to treating relapsed/refractory cancers. The initial Phase 1 clinical trial of the...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,444 Project Grant to Cancure LLC (DBA Canzx Biotherapeutics) to conduct a feasibility study of a novel NK and CD8 T cells stimulating agent. The project aims to develop a complex molecule that can be used as an additive during NK and antigen-specific CD8 T cell expansion to enable their superior efficacy in treating solid tumors. The key objectives are to address the challenges of persistence and...
- The University of Texas MD Anderson Cancer Center received a $1,824,620.00 Project Grant award from the National Cancer Institute under the Cancer Centers Support Grants (CFDA 93.397) program on August 19, 2025. The overarching goal of this 5-year award is to reduce morbidity and mortality from sarcomas through innovative translational research focused on immunologic and targeted treatments. The award supports two key projects: 1) developing an adoptive cellular therapy platform for chordoma...
- The University of Texas MD Anderson Cancer Center was awarded a $112,230 Project Grant from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program, effective September 10, 2025 through September 9, 2028. The grant supports research to investigate the ability of a novel dendritic cell vaccination approach, alone and in combination with immune checkpoint blockade, to generate diverse and effective anti-tumor CD8+ T cell responses through the induction of "antigen...